Canada Generic Drug Market Price, Size, Share, Top Brands & Companies, and Research Report by 2026

Published February 7, 2023

The latest report by IMARC Group, titled “Canada Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026”, offers a comprehensive analysis of the industry, which comprises insights on the Canada generic drug market price. The report also includes competitor and regional analysis, and contemporary advancements in the market.

The Canada generic drug market reached a value of US$ 6.4 Billion in 2020. Looking forward, IMARC Group expects the market to reach a value of US$ 7.0 Billion by 2026.

Generic drugs refer to medications that have the same active ingredients and therapeutic effect as that of a branded drug. These drugs can be oral, intravenous, intramuscular, topical or inhalant. They do not require extensive marketing due to the established safety and efficacy profile of their branded counterparts. Generic drugs can only be introduced once the patent protection of the associated brand-name drug has expired. In recent years, there has been a rise in healthcare spending in Canada on account of the growing geriatric population, which in turn has resulted in high demand for pharmaceutical products like generic drugs. Also, an increase in government policies supporting research and development (R&D) have further strengthened Canada’s expertise in niche areas such as biologics and oncology.

Note: We are updating our reports, If you want the latest primary and secondary data (2023-2028/2022-2027) with Cost Module, Business Strategy, Competitive landscape, etc. Click request free sample report, the report will be delivered to you via email within 24 to 48 hours.

Request Free Sample Report:

Canada Generic Drug Market Trends:

A large population of Canada has been diagnosed with numerous lifestyle conditions such as cardiovascular diseases (CVDs), cancer, chronic respiratory diseases (CRDs) and diabetes. This, along with the aging population, has created a heightened demand for cost-effective drugs in the country. As generic drugs are economical counterparts of branded drugs, they play a crucial role in lowering the overall treatment costs of these diseases. Owing to this, the Government of Canada is introducing supportive policies, which are favorable for the generic medicines industry.

For instance, the Government has introduced public drug programs, such as the Ontario Drug Benefit (ODB) Program and Trillium Drug Program, as an initiative to provide universal healthcare in the country. Although these programs utilize both brand-name and generic drugs, they encourage physicians and patients to opt for generic medicines wherever available, so as to lower the overall drug expenditure. Moreover, several leading companies are engaged in research and development (R&D) activities to create complex and differentiated products. This is done either through acquisitions or by building their capabilities.

Explore the Full Report with TOC & List of Figures:

Competitive Landscape:                                      

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

Some of these key players include:            

  • Teva Pharmaceutical Industries Limited
  • Apotex Inc.
  • Sandoz Inc.
  • Sun Pharma Industries Ltd.
  • Pharmascience Inc.
  • Mylan N.V

Key highlights of the Report:

  • Market Performance
  • Market Outlook
  • Porter’s Five Forces Analysis
  • Market Drivers and Success Factors
  • SWOT Analysis
  • Value Chain
  • Comprehensive Mapping of the Competitive Landscape

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

Explore Latest Blogs by IMARC Group:

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

IMARC Group          
134 N 4th St. Brooklyn, NY 11249, USA
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800